TransMedics Group, Inc. (NASDAQ:TMDX) Shares Purchased by Peregrine Capital Management LLC

Peregrine Capital Management LLC increased its stake in shares of TransMedics Group, Inc. (NASDAQ:TMDX) by 64.0% in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 66,140 shares of the company’s stock after purchasing an additional 25,814 shares during the period. Peregrine Capital Management LLC owned 0.20% of TransMedics Group worth $4,124,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds have also recently modified their holdings of TMDX. Creative Planning raised its position in shares of TransMedics Group by 11.9% during the 3rd quarter. Creative Planning now owns 10,262 shares of the company’s stock worth $1,611,000 after purchasing an additional 1,089 shares during the last quarter. Guidance Capital Inc. acquired a new position in shares of TransMedics Group during the 3rd quarter worth about $370,000. Louisiana State Employees Retirement System acquired a new position in shares of TransMedics Group during the 3rd quarter worth about $2,528,000. State of Alaska Department of Revenue acquired a new position in shares of TransMedics Group during the 3rd quarter worth about $2,560,000. Finally, New York State Teachers Retirement System acquired a new position in shares of TransMedics Group during the 3rd quarter worth about $1,217,000. Institutional investors and hedge funds own 99.67% of the company’s stock.

TransMedics Group Stock Performance

TransMedics Group stock opened at $79.42 on Thursday. The firm has a 50 day simple moving average of $66.04 and a 200-day simple moving average of $105.44. TransMedics Group, Inc. has a 1-year low of $55.00 and a 1-year high of $177.37. The company has a debt-to-equity ratio of 2.42, a current ratio of 8.20 and a quick ratio of 7.33. The stock has a market cap of $2.67 billion, a price-to-earnings ratio of 84.49 and a beta of 2.12.

Wall Street Analysts Forecast Growth

A number of research firms have commented on TMDX. Canaccord Genuity Group cut their price objective on shares of TransMedics Group from $109.00 to $104.00 and set a “buy” rating for the company in a report on Wednesday, November 20th. JPMorgan Chase & Co. reiterated a “neutral” rating and issued a $75.00 price objective (down previously from $116.00) on shares of TransMedics Group in a report on Tuesday, December 17th. Oppenheimer reiterated an “outperform” rating and issued a $125.00 price objective on shares of TransMedics Group in a report on Tuesday, December 3rd. Robert W. Baird cut their price objective on shares of TransMedics Group from $150.00 to $120.00 and set an “outperform” rating for the company in a report on Wednesday, December 11th. Finally, TD Cowen cut their price objective on shares of TransMedics Group from $175.00 to $120.00 and set a “buy” rating for the company in a report on Monday, November 18th. Three equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $122.70.

Insider Activity

In related news, insider Tamer I. Khayal sold 1,084 shares of the stock in a transaction that occurred on Monday, December 2nd. The shares were sold at an average price of $86.40, for a total transaction of $93,657.60. Following the completion of the transaction, the insider now owns 20,843 shares of the company’s stock, valued at approximately $1,800,835.20. This trade represents a 4.94 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 7.00% of the company’s stock.

TransMedics Group Company Profile

TransMedics Group, Inc, a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body.